drugset / Trial / NCT02117258
Z-360 Plus GEM in Subjects With Metastatic Pancreatic Adenocarcinoma
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The primary objective of this study is to compare the efficacy of GEM plus Z-360 versus GEM plus placebo on the overall survival (OS) in subjects with metastatic Pancreatic Adenocarcinoma.
Timeline
- Start
- 2014-04
- Primary completion
- 2016-07
- Completion
- 2017-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NASTORAZEPIDE CALCIUM | Unknown | 60 mg | Oral |
| Subject | NASTORAZEPIDE CALCIUM | Unknown | 120 mg | Oral |
| Subject | NASTORAZEPIDE CALCIUM | Unknown | 240 mg | Oral |
| Background | Gemcitabine | Small molecule | 1000 mg/m2 | Intravenous |